GlaxoSmithKline (NYSE:GSK) is a British multinational pharmaceutical company headquartered in London, England. The company focuses on the research, development, manufacturing and marketing of prescription medicines and vaccines. GSK maintains a global presence, supplying health products to markets across North America, Europe, Asia, Latin America and emerging economies.
In its pharmaceuticals segment, GSK develops treatments in areas such as respiratory disease, HIV/infectious disease and oncology. Its portfolio includes respiratory medicines like Breo Ellipta and Anoro Ellipta, as well as HIV therapies such as Tivicay and Triumeq. GSK’s vaccines division produces immunizations against meningitis, shingles and influenza, with well-known brands including Bexsero, Shingrix and Fluarix. The company supports its marketed products with an extensive pipeline of clinical-stage candidates in immunology, oncology and rare diseases.
GSK was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, creating one of the world’s largest research-based healthcare companies. In July 2022, GSK completed the spin-off of its consumer healthcare business as Haleon, sharpening its strategic focus on pharmaceuticals and vaccines. The company operates research centers in the UK, the United States and other key innovation hubs.
Under the leadership of Chief Executive Officer Emma Walmsley, appointed in 2017, GSK emphasizes collaborations with academic institutions, biotech partners and public-sector organizations. The company continues to invest heavily in R&D, aiming to bring new therapies and preventive vaccines to patients worldwide.